CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, announced today that dosing was initiated in a Phase 1/2 trial of 131I-TM601 delivered intravenously (IV) for the treatment of adult patients with recurrent malignant glioma. The trial will focus on investigating the tolerability, safety, and therapeutic efficacy of multiple doses of 131I-TM601 when administered intravenously. This study follows the clinical confirmation in a now completed Phase 1 trial that IV-delivered 131I-TM601 crosses the blood-brain barrier and specifically targets and binds to tumor tissue.
